Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
about
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unitAntimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patientsTreatment and prophylaxis of invasive candidiasisRisk prediction for invasive candidiasisEpidemiology of invasive candidiasis: a persistent public health problemEffect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.Effect of antifungal therapy timing on mortality in cancer patients with candidemiaCanadian clinical practice guidelines for invasive candidiasis in adults.β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot studyEMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trialClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study.Economic considerations of antifungal prophylaxis in patients undergoing surgical proceduresStudy on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Invasive candidiasis in non-hematological patients.Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol.Emerging pan-resistance in Trichosporon species: a case report.Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study.Risk factors for invasive fungal disease in critically ill adult patients: a systematic review.Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units.Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.Manipulation of Host Diet To Reduce Gastrointestinal Colonization by the Opportunistic Pathogen Candida albicansMultidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Pharmacokinetic evaluation of fluconazole in critically ill patients.Candida peritonitis: an update on the latest research and treatments.Occurrence, presentation and treatment of candidemia.Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care.An Italian consensus for invasive candidiasis management (ITALIC).Invasive fungal infections in the ICU: how to approach, how to treat.Untargeted antifungal therapy in adult patients with complicated intra-abdominal infection: protocol for a systematic review with meta-analysis.The current treatment landscape: candidiasis.Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers.Clinical factors affecting costs in patients receiving systemic antifungal therapy in intensive care units in Greece: Results from the ESTIMATOR study.Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients.IgG1 anti-cell wall and IgG2 anti-phosphopeptidomannan antibodies in the diagnosis of invasive candidiasis and heavy Candida colonization.Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies.
P2860
Q21194915-6C2EAB0D-5BF0-4792-9357-15FD3A97CBF8Q26739860-0D5D247D-03F7-4590-89D1-9722141626AAQ26852351-86CA168F-F0D8-4AC3-AECE-1A6DB74E96EAQ27001567-66C2311D-6C87-48DD-9AD3-E8193B7DCD0AQ27023082-774A11DF-129B-4B43-8207-9690FB4B8D8FQ29616758-C12A89B9-16B2-4D42-89C6-5E5CFF819BECQ30405312-AF686186-4704-40BF-B5DB-D344AF75B1D3Q33559164-35D2FDB1-97D6-4060-990B-C4A80FEC219EQ34237335-F823C64C-C369-4FE3-8CD9-6917A8F7E49FQ34374081-B1713D45-5B4D-4C01-8FBA-ECFB5A196E8CQ34465297-46B9D3E2-88E5-43E9-B597-A392F76665A2Q34505582-7F54EA0A-0B93-434D-B1EF-FD275B64C4C3Q34528342-2613F3F0-86FA-4115-8C34-2962A1356030Q34574154-E8A89713-5965-4BA5-93D7-A52F0747B330Q34724824-F2628BEC-1323-4ECD-B251-208FAA2B8A7FQ35010671-B86BE095-AAEA-4017-9671-095D5E80A62CQ35193171-33060F10-E3AC-4DDD-8078-3B2EDBFF146CQ35988869-DA8823E2-6F0B-49C6-B506-A17ACD9B4C0AQ36070524-7BA778FE-694C-4B6F-BCFB-01B9D133AC0BQ36073057-A3D0944F-685F-46A8-8C49-036D47DDEA29Q36128742-69CCABB2-BF7B-4A90-B361-67890D4E6EC3Q36822025-E7D622CF-640F-4765-84F4-A980D1AC06A4Q36891368-94BF22BC-6A8C-4E6E-AB17-F40A7FDF96ACQ37098160-0915653D-138E-4D54-A46C-1DE72BA95F1BQ37453850-6E5BFA8E-7557-4F2E-AF90-6CEF218BBCA2Q37759256-1E6AACEC-A91A-4721-A61A-EB31271257D6Q37889382-035C012B-6715-43C7-B004-F44C908F7990Q37924819-F6DF57E3-C29F-4E9C-9037-E577AF714A7AQ37942794-0DA257B4-F98D-4588-9FFD-B7083DBBE59CQ38061190-DB8CC590-EC0C-4F7E-95D2-A46A1AEE7E3FQ38073717-B843001E-906C-4278-AAB2-CD17AEEB0824Q38165883-9701F140-9332-4243-920D-C5F10972B465Q38180287-D040298A-E1DE-4840-8709-5F68748B43E3Q38758069-9D58D734-81FD-4EFE-B794-63C758F4435CQ39018200-8765292C-90D1-41D3-9C12-AA5357EC833BQ39478831-94FA9ABC-E465-44CE-8E66-77314F7ACAC2Q40060340-C88ABFC1-B59B-4B7F-95D5-C0C0200CC1BBQ40549479-312EF4D7-108B-49ED-9DFC-A1DA1BE10BF4Q41114356-29FE3FE3-2BD1-4334-B2EB-D74C5E4DA5DEQ43707773-DB2BBE6B-A666-4957-A9D2-93BB2AF4109B
P2860
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antifungal agents for preventi ...... of randomized clinical trials.
@ast
Antifungal agents for preventi ...... of randomized clinical trials.
@en
type
label
Antifungal agents for preventi ...... of randomized clinical trials.
@ast
Antifungal agents for preventi ...... of randomized clinical trials.
@en
prefLabel
Antifungal agents for preventi ...... of randomized clinical trials.
@ast
Antifungal agents for preventi ...... of randomized clinical trials.
@en
P50
P356
P1476
Antifungal agents for preventi ...... of randomized clinical trials.
@en
P2093
E Geoffrey Playford
P304
P356
10.1093/JAC/DKI491
P407
P577
2006-02-03T00:00:00Z